Oragenics is developing novel antibiotics and probiotics through synthetic biology collaborations. For antibiotics, they are focusing on lantibiotics, a class of naturally produced antibacterial peptides, with a lead compound called MU1140 showing promise against MRSA, VRE and C. difficile. For probiotics, they are engineering bacteria to produce and deliver therapeutics locally for oral diseases. Their OTC probiotic product ProBiora3 supports oral health currently. Upcoming milestones include animal studies on MU1140 in 2014 and generating genetically modified probiotic prototypes in 2014-2015.
Dr. Cyril Gay - Alternatives to AntibioticsJohn Blue
Alternatives to Antibiotics - Dr. Cyril Gay, Senior National Program Manager, USDA Agricultural Research Service (ARS), from the 2017 NIAA Annual Conference, U.S. Animal Agriculture's Future Role In World Food Production - Obstacles & Opportunities, April 4 - 6, Columbus, OH, USA.
More presentations at http://www.trufflemedia.com/agmedia/conference/2017_niaa_us_animal_ag_future_role_world_food_production
Vaccine Development & GMP Manufacturing - Creative BiolabsCreative-Biolabs
This slide is about knowleges of vaccine development. It mainly explains the following contents: goals of vaccine development, vaccine development stages, vaccine manufacturing, challenges for vaccine development, and the services Creative Biolabs can provide.
This report covers patent analysis on types and application areas of probiotics, their research trends and key intellectual property indicators. This article was prepared by mining patent data using Patent iNSIGHT Pro, a comprehensive patent analysis platform that helps one accelerate time-to-decision from patent analysis.
Dr. Cyril Gay - Alternatives to AntibioticsJohn Blue
Alternatives to Antibiotics - Dr. Cyril Gay, Senior National Program Manager, USDA Agricultural Research Service (ARS), from the 2017 NIAA Annual Conference, U.S. Animal Agriculture's Future Role In World Food Production - Obstacles & Opportunities, April 4 - 6, Columbus, OH, USA.
More presentations at http://www.trufflemedia.com/agmedia/conference/2017_niaa_us_animal_ag_future_role_world_food_production
Vaccine Development & GMP Manufacturing - Creative BiolabsCreative-Biolabs
This slide is about knowleges of vaccine development. It mainly explains the following contents: goals of vaccine development, vaccine development stages, vaccine manufacturing, challenges for vaccine development, and the services Creative Biolabs can provide.
This report covers patent analysis on types and application areas of probiotics, their research trends and key intellectual property indicators. This article was prepared by mining patent data using Patent iNSIGHT Pro, a comprehensive patent analysis platform that helps one accelerate time-to-decision from patent analysis.
This ppt explains about molecular farming, history of molecular farming, importance, basic process underlying it, its application in agriculture and its limitations
Our professional Biotechnology assignment help writers can work under strict deadlines and are dedicated to provide high quality biotechnology assignment help at reasonable rates.
Visit : https://www.essaycorp.com/biotechnology-assignment-help.html
phage therapy is the use of bacteriophages to kill pathogenic bacterial cells. Bacteriophages are bacterial parasites that invade bacterial cells and engulf them like blue whale fish kills euphausiids and copepodsand in sea .
new applications and biotechnological inventions are continuously being developed to help improve our world. Here are few breakthrough biotechnological innovations currently underway.
Platform Technologies to Accelerate Novel Vaccine Development and ManufacturingMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3jmLYHu
State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed.
The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform.
In this webinar, you will learn:
• Benefits of platform technologies in vaccine development
• Key considerations when deciding between platforms
• Vaccine pipeline analysis and selected case studies
Presented by:
David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
A bacteriocin discovery pipeline called BOA. Bacteriocin are ribosomal synthesize anti bacterial compounds. BOA provides leads for bacteriocin discovery
Application of probiotics in complex treatment of tuberculosisIJERA Editor
The probiotic bacteria possessing ability to suppress growth of Mycobacterium B5 are revealed. Antagonistic
activity in selected strains studied during the growth on various nutrient media. Strains adapted to the low pH
exposure. They are steady against a number of the antibiotics, used at tuberculosis treatment. This testifies to the
prospects of further studies on the use of probiotics in the
This ppt explains about molecular farming, history of molecular farming, importance, basic process underlying it, its application in agriculture and its limitations
Our professional Biotechnology assignment help writers can work under strict deadlines and are dedicated to provide high quality biotechnology assignment help at reasonable rates.
Visit : https://www.essaycorp.com/biotechnology-assignment-help.html
phage therapy is the use of bacteriophages to kill pathogenic bacterial cells. Bacteriophages are bacterial parasites that invade bacterial cells and engulf them like blue whale fish kills euphausiids and copepodsand in sea .
new applications and biotechnological inventions are continuously being developed to help improve our world. Here are few breakthrough biotechnological innovations currently underway.
Platform Technologies to Accelerate Novel Vaccine Development and ManufacturingMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3jmLYHu
State-of-the-art vaccine technologies are transforming vaccine development, and solutions for fast and reliable production are needed.
The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platform.
In this webinar, you will learn:
• Benefits of platform technologies in vaccine development
• Key considerations when deciding between platforms
• Vaccine pipeline analysis and selected case studies
Presented by:
David Loong, Ph.D, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
Josephine Cheng, Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy
A bacteriocin discovery pipeline called BOA. Bacteriocin are ribosomal synthesize anti bacterial compounds. BOA provides leads for bacteriocin discovery
Application of probiotics in complex treatment of tuberculosisIJERA Editor
The probiotic bacteria possessing ability to suppress growth of Mycobacterium B5 are revealed. Antagonistic
activity in selected strains studied during the growth on various nutrient media. Strains adapted to the low pH
exposure. They are steady against a number of the antibiotics, used at tuberculosis treatment. This testifies to the
prospects of further studies on the use of probiotics in the
Exeo Entertainment, Inc. is a manufacturing company concentrating on developing innovative products that fill a clearly defined need in today’s interactive entertainment industry. Featured products include the Zaaz™ smart TV keyboards, Patented Psyko Krypton™ 5.1 gaming headphones, Krankz Bluetooth music headphones, an Android® based portable gaming system, and the Extreme Gamer® -the world’s first multi–disc game changer.
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...RedChip Companies, Inc.
Big North is a graphite development and exploration company with projects in Mexico and Canada
Owns three past producing amorphous graphite mines in Sonora, Mexico
Currently test mining at the Nuevo San Pedro amorphous graphite mine.
Owns high quality large-flake graphite exploration target in Ontario
The era of instantaneous pathogen detection is finally here. Opteev's Multiplex Biosensor is able to detect and identify any pathogen in just 60 seconds with over 99% accuracy, allowing for the first truly comprehensive multiplex diagnostics at the Point-of-Care while revolutionizing environmental monitoring, food safety, at at-home testing. Witness the unmatched speed, precision, and accessibility of Opteev's Multiplex Biosensor. Witness the dawn of a new era.
This report takes a look into the patenting activity around probiotics uncovering the companies, inventors, intellectual property trends and other key indicators. Probiotics are live microorganisms thought to be beneficial to the host organism.
This report graphically analyzes probiotics markets from many perspectives, categorizes and highlights the key companies involved, defines unique keywords. This report also covers the global probiotics marketplace. It focuses particularly on the markets and opportunities for probiotics in medical applications, formulations, processing technologies, and various microbes. The study considers future opportunities for new application markets.
This report was prepared by mining patent data using Patent iNSIGHT Pro, a comprehensive patent analysis platform that helps one accelerate time-to-decision from patent analysis activities.
Published: Oct 25, 2011
Life Technologies (now Thermo Fisher Scientific) combines next-generation sequencing, in silico gene design and synthesis, synthetic biology products, and manufacturing capabilities to form a comprehensive synthetic vaccine development workflow.
“The Coin Tree is a cloud-based storage, insurance, and payment processing platform for bitcoin that leverages cutting edge transactional security to serve the ever expanding virtual currency community."
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
DRONE Aviation Corp (DRNE) was formed in April 2014 to penetrate the rapidly growing Unmanned Aerial Systems (UAS) business in U.S. and abroad for government and commercial customers.
DRNE’s mission is to aggressively penetrate the expanding Drone market with our unique Tethered Drones, which are currently being fielded to the U.S. Department of Defense and State and Local municipalities.
DRNE owns and operates Florida-based Lighter Than Air Systems Corp (LTAS), a developer and supplier of unique and specialized aerial solutions to the U.S. Government, State municipalities, and commercial entities.
InterCloud Systems Incorporated is a single - source provider of end - to - end IT technology and telecom solutions to the ent erprise, service provider, and g overnment markets through “Cloud Platforms” and professional services. “Cloud Comput ing”, is defined as the use of computing resources (compute, NTK, Storage) that are delivered as a managed service over a network. InterCloud offers its service provider custo mers the ability to utilize “cloud” solutions inside their existing network footp rint as well as in a “white label environment” so it can offer a suite of cloud products under their own brand, delivered over the broadband services it presently sell s . ICLD’s cloud services include infrastructure as a service (IaaS), platform as a servi ce (PaaS), and software as a service (SaaS) .
The nuclear energy industry has lain stagnant for over 30 years and has suffered from missteps and perception issues.
Lightbridge is here to innovate and change the conversation. About: Lightbridge is a U.S. nuclear energy company based in McLean, Virginia with operations in Abu Dhabi, Moscow and London. The Company develops proprietary, proliferation resistant, next generation nuclear fuel technologies for current and future nuclear reactor systems. The Company also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. Lightbridge's breakthrough fuel technology is establishing new global standards for safe and clean nuclear power and leading the way to a sustainable energy future. Lightbridge consultants provide integrated strategic advice and expertise across a range of disciplines including regulatory affairs, nuclear reactor procurement and deployment, reactor and fuel technology and international relations. The Company leverages those broad and integrated capabilities by offering its services to commercial entities and governments with a need to establish or expand nuclear industry capabilities and infrastructure.
Richfield Oil & Gas Company (OTCQX: ROIL) is an independent exploration and production company headquartered in Salt Lake City, Utah. The Company’s current oil production flows from wells in fields located in Kansas and Wyoming. In addition to several thousand acres in Kansas, Richfield also owns strategically-located exploratory leases in central Utah on trend to major oil discoveries.
NeoStem, Inc. (“NeoStem” or the “Company”), a biopharmaceutical company, is capitalizing on the paradigm shift occurring in medicine by engaging in the development and manufacture of cellular therapies for oncology, immunology, and regenerative medicines in the United States. The Company anticipates that cell therapy will play a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.
Founded in 1886, American Water (NYSE: AWK) is the largest publicly traded U.S. water and wastewater utility company. With headquarters in Voorhees, N.J., the company employs approximately 6,600 dedicated professionals who provide drinking water, wastewater and other related services to an estimated 14 million people in more than 40 states and parts of Canada. Our January Online Conference was attended by nearly 5,000 investors. Don't miss your chance to listen to leading small-cap company executives who will provide detailed overviews of their businesses through video presentations and live Q&A sessions.
Direct Insite (“DIRI”) provides cloud-based, ERP-agnostic solutions that automate Accounts Payable (AP) and Accounts Receivable (AR) invoice processes for Global 3000 companies. Their solutions include invoice validation, order matching, consolidation, dispute handling and e-payment processing. DIRI helps clients eliminate manual processes and costs associated with doing everything on paper. By migrating from paper to electronic, DIRI can reduce transactions costs 50-70% and reduce time by 80%. Current clients include Siemens, HP, IBM, Saint-Gobain, Shell Oil, and Hyatt with a Global vendor network of 350,000+ suppliers.
Lattice Incorporated (“Lattice” or the “Company”), founded in 1973, provides secure communications and information technology, specializing in deploying advanced technology and services to create innovative, cost - effective solutions for the Company’s global customers. The Company provides both wholesale and direct services to correctional facilities and their service providers in the U.S., Canada and Europe. Expansion of Lattice’s direct and wholesale services, including increased techno logy equipment and software sales to wholesale customers, is expected to drive revenue growth and increased margins in the quarters ahead
Quadrant 4 Systems Corporation is a leading provider in of health exchange platforms, innovative software products and proprietary SMAC (social media, mobility, analytics and cloud computing) solutions to enterprise clients in Retail and Manufacturing, Media and Publishing, Financial Services and Health Care sectors.
Energy Fuels is the nation's leading conventional uranium producer, supplying approximately 25% of the uranium produced in the U.S. (based on FY-2013 deliveries). The Company also has the capability to be a significant producer of vanadium. Energy Fuels owns and operates the White Mesa Mill, which is the only conventional uranium mill currently operating in the U.S. The mill is capable of processing 2,000 tons per day of uranium ore and producing up to 8 million lbs. of U3O8 per year (depending on ore grade).
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Chandrima Spa Ajman is one of the leading Massage Center in Ajman, which is open 24 hours exclusively for men. Being one of the most affordable Spa in Ajman, we offer Body to Body massage, Kerala Massage, Malayali Massage, Indian Massage, Pakistani Massage Russian massage, Thai massage, Swedish massage, Hot Stone Massage, Deep Tissue Massage, and many more. Indulge in the ultimate massage experience and book your appointment today. We are confident that you will leave our Massage spa feeling refreshed, rejuvenated, and ready to take on the world.
Visit : https://massagespaajman.com/
Call : 052 987 1315
COVID-19 PCR tests remain a critical component of safe and responsible travel in 2024. They ensure compliance with international travel regulations, help detect and control the spread of new variants, protect vulnerable populations, and provide peace of mind. As we continue to navigate the complexities of global travel during the pandemic, PCR testing stands as a key measure to keep everyone safe and healthy. Whether you are planning a business trip, a family vacation, or an international adventure, incorporating PCR testing into your travel plans is a prudent and necessary step. Visit us at https://www.globaltravelclinics.com/
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)blessyjannu21
Neurological system includes brain and spinal cord. It plays an important role in functioning of our body. Encephalitis is the inflammation of the brain. Causes include viral infections, infections from insect bites or an autoimmune reaction that affects the brain. It can be life-threatening or cause long-term complications. Treatment varies, but most people require hospitalization so they can receive intensive treatment, including life support.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
Feeding plate for a newborn with Cleft Palate.pptxSatvikaPrasad
A feeding plate is a prosthetic device used for newborns with a cleft palate to assist in feeding and improve nutrition intake. From a prosthodontic perspective, this plate acts as a barrier between the oral and nasal cavities, facilitating effective sucking and swallowing by providing a more normal anatomical structure. It helps to prevent milk from entering the nasal passage, thereby reducing the risk of aspiration and enhancing the infant's ability to feed efficiently. The feeding plate also aids in the development of the oral muscles and can contribute to better growth and weight gain. Its custom fabrication and proper fitting by a prosthodontist are crucial for ensuring comfort and functionality, as well as for minimizing potential complications. Early intervention with a feeding plate can significantly improve the quality of life for both the infant and the parents.
Veterinary Diagnostics Market PPT 2024: Size, Growth, Demand and Forecast til...IMARC Group
The global veterinary diagnostics market size reached US$ 6.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.3% during 2024-2032.
More Info:- https://www.imarcgroup.com/veterinary-diagnostics-market
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
Under Pressure : Kenneth Kruk's StrategyKenneth Kruk
Kenneth Kruk's story of transforming challenges into opportunities by leading successful medical record transitions and bridging scientific knowledge gaps during COVID-19.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareDr. David Greene Arizona
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
OGEN Presentation April 2014
1. 1
Certain statements made in this presentation include forward-looking actions that
Oragenics, Inc. (“Oragenics,” or the “Company”) anticipates based on certain
assumptions. These statements are indicated by words such as “expect,”
“anticipate,” “should” and similar words indicating uncertainty in facts, figures and
outcomes. Such statements are made pursuant to the Safe Harbor Provisions of the
Private Securities Litigation Reform Act of 1995. While Oragenics believes that the
expectations reflected in such forward-looking statements are reasonable, it can give
no assurance that such statements will prove to be correct. The risks associated with
the Company are detailed in the Company’s various reports filed by the Company with
the Securities and Exchange Commission.
Safe Harbor Statement
2. 2
At A Glance - Oragenics
• Expertise in bacteria – especially related to the oral cavity
• Lantibiotics – Capable of killing bacteria, including
antibiotic-resistant strains
• Next Generation Probiotics – Designed to be
therapeutically useful
• ProBiora3® - OTC probiotic used to improve overall oral
health
3. 3
At A Glance - Oragenics
• NYSE MKT: OGEN (market cap ~$126 M)
• Founded in 1999
• Based in Tampa, FL
• Experienced management team
4. 4
Overview
¤ Leverage expertise in lantibiotics and probiotics with
Intrexon’s leading synthetic biology platform via two
exclusive channel collaborations (ECCs) to develop novel
biotherapeutics:
1. Lantibiotics: novel class of peptide antibacterial compounds
produced by specific strains of bacteria
2. Next Generation Probiotics: bacteria-based biotherapeutics for
oral cavity, throat, sinus, and esophagus diseases
¤ Market proprietary OTC oral care probiotics (ProBiora3®)
5. Investor Presentation April 9, 2014
Engineering
New
An/bio/cs
and
Probio/cs
Through
Synthe/c
Biology
Lan/bio/cs
and
the
Need
for
New
An/bio/cs
6. 6
Serious Need for New Antibiotics
Sept. 2013 CDC report highlighted
serious threats of antibiotic-resistant
infections and need for new
antibiotics:
¤ >2 million infections and ~23,000 deaths
each year in U.S. caused by resistant
microbes
¤ >$20 billion in direct healthcare spending
from resistance infections
¤ >$35 billion in additional costs due to lost
productivity
“Antibiotic Resistance Threats in the United States, 2013” U.S. Department of Health and Human Services Centers for
Disease Control and Prevention
7. 7
Trends Support CDC Concerns
Resistance Increases While Approvals Decrease
8. 8
Lantibiotics
A Promising Solution to the Growing Health Crisis
of Antibacterial Resistance
¤ Novel class of peptide antibacterial compounds:
• Naturally-produced by variety of bacterial strains to attack
competing gram-positive bacterial strains
• >50 known lantibiotics and a very large number of potential
analogs
• Pipeline of new compounds to target resistant infections
• Development as commercially-viable products previously limited
by technological hurdles
9. 9
Lantibiotics
A Promising Solution to the Growing Health Crisis
of Antibacterial Resistance
¤ Well-positioned to bring lantibiotics to market:
• Intrexon collaboration expected to enable production of
lantibiotics at commercial scale
• Progress to date through Intrexon/Oragenics ECC
! Achieved significant increase in production titer yield
! Developing robust purification methods compared to
traditional approaches
! Completed POC that genetically modified bacteria can produce
MU1140 and analogs
10. 10
Lead Lantibiotic Compound MU1140
¤ Initial focus on MU1140, a lantibiotic shown to be effective against:
• Methicillin-resistant Staphylococcus aureus (MRSA)
• Vancomycin-resistant Enterococcus (VRE)
• Clostridium difficile (C. diff)
• Resistant Tuberculosis and others
¤ Preliminary preclinical data suggests:
• Excellent therapeutic index
• Minimal cytotoxicity in vitro using mouse and human cell lines; minimal
immunogenicity
• Maximum tolerated dose in mice and rats >50 mg/Kg
• In vivo efficacy observed in a pilot rat peritonitis model using S. aureus (60xLD50)
• Apparent synergy with aminoglycosides
11. 11
ECC with Intrexon
Platform for Engineering Bacterial Systems
Through Synthetic Biology
Inventoried DNA Modules
Genetically Modified
Bacterial Cell
12. 12
ECC with Intrexon
Development of lantibiotics for treatment of
infectious diseases in humans and animals
¤ Application of engineering principles to the design of
living organisms and their constituent parts (DNA,
proteins, and cells)
¤ Intrexon’s toolset of modular molecular and cellular
systems expected to enable the engineering of specific
functionality into cells to allow industrial scale production
of lantibiotics
13. 13
ECC with Intrexon
Lantibiotics – For Resistant Bacterial Infections
Bacteria
Cell
Extract genes
responsible for
lantibiotic
production
from native
bacteria…
…insert
genes into
modified
bacteria to
maximize
lantibiotic
production…
…and produce MU1140
and pipeline lantibiotics
via fermentation at
commercial scale.
Lantibiotics
(50+ known)
14. 14
¤ Matrix of early experiments initiated to screen MU1140 (and several
analogs/homologs) for determining primary efficacy (e.g. MICs, MTD,
primary efficacy in animals, protein binding, etc.)
¤ Fermentation optimization/scale-up purification in progress
¤ IND filing expected by 2H 2015*
2Q13
3Q13
4Q13
1Q14
2Q14
3Q14
4Q14
Animal
studies
Animal
studies
Pre-‐IND
FDA
mee4ng
IND*
Plan for MU1140
First of 50+ Known Lantibiotics and Analogs
* Current estimate may change depending on FDA pre-IND meeting
results
15. 15
Rising Market Demand for Novel
Antibiotic Platforms
$
Market cap:
approx. $83M
Deal size:
approx. $775M total
approx. $10M upfront
Cubist
Market cap:
approx. $4.2B
Validated Technology
Leads to Deals
Commercial
Oragenics Cubist
Preclinical
Rib-‐X
and
Sanofi
Significant valuations for “Single Antibiotic Product” companies –
Oragenics has potential to generate a pipeline of lantibiotics
Cubist/Trius/Op/mer
Acquisi/ons
Deal size:
approx. $818M Trius
approx. $808M Optimer
Cubist Acquisitions
(7/31/13)
Approved/Late Stage
16. Investor Presentation April 9, 2014
Engineering
New
An/bio/cs
and
Probio/cs
Through
Synthe/c
Biology
Next
Genera/on
Probio/cs
For
Therapeu/c
Use
17. 17
Next Generation Probiotics
Potential to Revolutionize Probiotics for Oral
Diseases
¤ Developing novel probiotics focusing on treatment of patients with
oral cavity, throat, sinus, and esophageal diseases through ECC with
Intrexon
¤ Expect to genetically manipulate bacteria similar to lantibiotics
program
• Beneficial
bacteria
naturally
part
of
the
human
oral
cavity
microbiome
¤ Genetically-engineered bacterial strains designed to deliver and
release therapeutics locally at disease site to target pain
management, reduce inflammation, and improve patient outcomes
¤ Initial indications:
• Behçet’s
disease
• Recurrent
aphthous
stoma44s
(aka
canker
sores)
18. 18
Behçet’s
disease
¤ Chronic
relapsing
mul4-‐systemic
inflammatory
disorder
¤ Characterized
by
four
major
symptoms
(oral
aphthous
ulcers,
genital
ulcers,
skin
lesions,
and
ocular
lesions)
¤ Pa4ents
oLen
in
constant
pain
and
have
difficulty
ea4ng
¤ ~20,000
pa4ents
in
the
U.S.;
similar
for
Europe
19. 19
Recurrent
Apthous
Stoma44s
(aka
canker
sores)
¤ Painful
ulcers;
most
common
oral
mucosal
disease
known
¤ No
effec4ve
treatments
¤ ~200,000
pa4ents
in
the
U.S.
¤ Characterized
by
mul4ple,
recurrent,
small,
round,
or
ovoid
ulcers
¤ Usually
presents
first
in
childhood
or
adolescence
20. 20
Oragenics/Intrexon Solution
GM Probiotics For Oral Health
Bacteria
Cell
…insert genes
responsible for
production of
therapeutics
agent(s)…
…deliver new
therapeutic bacteria
into oral cavity to
produce therapeutic
benefits and supplement
natural oral microbiome.
Choose the
appropriate
bacterial strain
to engineer…
21. Investor Presentation April 9, 2014
Engineering
New
An/bio/cs
and
Probio/cs
Through
Synthe/c
Biology
ProBiora3® - Only OTC Probiotic
Product Specifically Designed for
Oral Health
22. 22
¤ Blend of 3 naturally occurring, non-pathogenic bacteria – S.oralis,
S.uberis, and S.rattus – available without prescription and taken daily
¤ “Good” probiotic bacteria compete for binding sites and nutrients with
“harmful” bacteria
¤ Release hydrogen peroxide to reduce population of pathogens in mouth
¤ Poor oral health linked to serious health problems, including heart
disease and diabetes
¤ Total consumer oral care market expected to reach $10.9 billion by
20141
¤ Also marketed for companion animals
ProBiora3® - OTC Product
First and Only Patented Probiotic Technology for
Oral Care
1‘The US Market for Oral Care Products (2009)’, published by Packaged Facts
23. 23
Experienced Management Team
John N. Bonfiglio, Ph.D., President, CEO & Director
¤ 30 years of management and pharmaceutical experience
¤ Prior CEO Argos Therapeutics, CEO Immune Response, CEO Peregrine Pharmaceuticals, COO Cypress Bio
¤ Senior Management positions at Allergan Pharmaceuticals and Baxter Healthcare
¤ MS and PhD in Chemistry, University of California, MBA Pepperdine University
Mike Sullivan, CFO
¤ Prior Senior-level financial positions for both publicly and privately held businesses
¤ Significant experience in product licensing and IP issues
¤ Strong background in both domestic and international retail operations
¤ Florida Certified Public Accountant, ex Big 4. MBA from The Florida State University
Dr. Martin Handfield, VP of Research & Development
¤ Former Tenured Associate Professor, College of Dentistry at The University of Florida
¤ Over 14 years experience with Oragenics
¤ Expert in biomarkers and research surrounding antimicrobials
¤ Over 40 publications and 6 patents
24. 24
Significant Accomplishments in
2013
Novel Antibiotics (Lantibiotics)
¤ Significantly increased yield of MU1140
¤ Identified two new potentially viable purification methods for
commercially producing MU1140
¤ Obtained proof of concept for genetically modified bacteria capable of
higher yields of MU1140 and potentially analogs
Next Generation Probiotics
¤ Established ECC with Intrexon – announced October 1, 2013
¤ Completed initial research program; commenced activity in 2014
Finance
¤ Raised $3.9M in PIPE with Intrexon to support new ECC
¤ Raised $11M in shelf-takedown
¤ Relisted on NYSE:MKT
25. 25
Upcoming Potential Milestones
Novel Antibiotics (Lantibiotics)
¤ Production of new lantibiotic analogs using genetically modified bacteria –
1H 2014
¤ Animal study results for MU1140/analog – 1H 2014
¤ Pre-IND meeting with FDA - 2H 2014
Next Generation Probiotics (Preliminary Timelines)
¤ Generation of next bacterial prototypes – 2H 2014
¤ GM probiotics producing cytokine therapeutics – Mid 2015
¤ Proof-of-concept of GM probiotic for therapeutic purposes in animals – 2H
2015